Intense activity in pharma

There is intense activity in the Greek pharmaceuticals sector, a testament to its growth potential.

Plans to invest in production, research and development under implementation until 2026 are worth €1.2 billion.

And then there are acquisitions: The latest development in the sector involves Famar, which, for the second time in four years, has changed hands. The formerly struggling company passed from Cyprus-based ECM Partners, to London-based MidEuropa, a private equity company. MidEuropa acquired the vast majority of Famar, leaving current shareholders with limited holdings.

Many of the investing Greek pharmaceuticals are looking outside the capital region: One favored destination is the industrial zone near the southern city of Tripoli, in the Peloponnese. Investment plans there, to the tune of €180 million, have been announced by Demo, Win Medica, part of the...